Your browser doesn't support javascript.
loading
Artificial intelligence applied to 'omics data in liver disease: towards a personalised approach for diagnosis, prognosis and treatment.
Ghosh, Soumita; Zhao, Xun; Alim, Mouaid; Brudno, Michael; Bhat, Mamatha.
Afiliação
  • Ghosh S; Transplant AI Initiative, Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada.
  • Zhao X; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Alim M; Transplant AI Initiative, Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada.
  • Brudno M; Transplant AI Initiative, Ajmera Transplant Program, University Health Network, Toronto, Ontario, Canada.
  • Bhat M; Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.
Gut ; 2024 Aug 22.
Article em En | MEDLINE | ID: mdl-39174307
ABSTRACT
Advancements in omics technologies and artificial intelligence (AI) methodologies are fuelling our progress towards personalised diagnosis, prognosis and treatment strategies in hepatology. This review provides a comprehensive overview of the current landscape of AI methods used for analysis of omics data in liver diseases. We present an overview of the prevalence of different omics levels across various liver diseases, as well as categorise the AI methodology used across the studies. Specifically, we highlight the predominance of transcriptomic and genomic profiling and the relatively sparse exploration of other levels such as the proteome and methylome, which represent untapped potential for novel insights. Publicly available database initiatives such as The Cancer Genome Atlas and The International Cancer Genome Consortium have paved the way for advancements in the diagnosis and treatment of hepatocellular carcinoma. However, the same availability of large omics datasets remains limited for other liver diseases. Furthermore, the application of sophisticated AI methods to handle the complexities of multiomics datasets requires substantial data to train and validate the models and faces challenges in achieving bias-free results with clinical utility. Strategies to address the paucity of data and capitalise on opportunities are discussed. Given the substantial global burden of chronic liver diseases, it is imperative that multicentre collaborations be established to generate large-scale omics data for early disease recognition and intervention. Exploring advanced AI methods is also necessary to maximise the potential of these datasets and improve early detection and personalised treatment strategies.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article